Antiresorptive related osteonecrosis of the Jaw Bone (ARONJ): A single Maxillofacial Unit Case series and Analysis

Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2

“…In the case of a patient with both cancer and MRONJ the goals of treatment should be prioritisation and support of continued oncological treatment, and preservation of quality of life by controlling pain, managing infection, and preventing the development of new areas of necrosis. 2 It is crucial that patients are kept informed about different treatments including the degree of invasion, and the possible disadvantages of the different treatments.…”

“…We followed the accepted updated criteria by the AAOMS to establish the diagnosis. 2 The following data were collected and divided into patientrelated information such as age, sex, whether they smoked, main disease and type of treatment (Table 1); and lesionrelated data such as site, number, size, and stage of lesions, and treatment given (Table 2). The patient's first complaint, relation to previous dental extractions, present signs and symptoms of MRONJ, presence of severe complications, and type of treatment given were also recorded.…”

“…bodies such as denosumab) seemed to lead to the same outcome -it was soon referred to as antiresorptive-related osteonecrosis of the jaw (ARONJ). 2 Since 2014 the American Association of Oral and Maxillofacial Surgeons (AAOMS) has recommended the use of the term "medication-related osteonecrosis of the jaw" (MRONJ). The change is justified to accommodate the growing number of cases of osteonecrosis that are associated with other antiresorptive and antiangiogenic treatments in patients who have not used bisphosphonates previously.…”

“…[10][11][12] The main goals of treatment for patients with cancer who present with MRONJ should be prioritisation and support of continued oncological treatment (mainly because such treatment outweighs the risk, incidence, or evolution of MRONJ lesions), and preservation of quality of life by controlling infection, pain, and the progression of bony necrosis. 2 Evolution under different treatments is evaluated clinically, and defined as complete healing of the lesion or transition to a less severe stage (according to the AAOMS classification).…”

Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw

“…In 2003, the first cases of what has become known as medication-related osteonecrosis of the jaw (MRONJ) were reported by Marx [1]. Initially, osteonecrosis was reported only after treatment with bisphosphonates and referred to as bisphosphonate-related osteonecrosis of the jaw (BRONJ) [2]. Since 2014, the term MRONJ was recommended by the American Association of Oral and Maxillofacial Surgeons (AAOMS) [3].…”